Intercontinental Exchange Inc. Common Stock vs Novartis AG — how do they compare? Intercontinental Exchange Inc. Common Stock trades at $155.35 (market cap $85.66B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 3.2× Intercontinental Exchange Inc. Common Stock's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals.
| ICE | NVS | |
|---|---|---|
Market Cap | $85.66B | $274.00B |
Volume | 1,638,131 | 1,852,137 |
Sector | Financials | Health |
52-Week High | $175.10 | $168.62 |
52-Week Low | $122.91 | $121.80 |
Enterprise Value | $103.57B | $315.32B |
Dividend Yield | 1.36% | 3.31% |
Typical Hold Time | — | 82 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Intercontinental Exchange provides technology and data services for financial institutions, corporations, and governments. Its businesses include exchanges and clearing, fixed-income data and analytics, and mortgage technology.
Read more on ICE →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →